QUALITY BY DESIGN (QBD): A COMPREHENSIVE UNDERSTANDING OF IMPLEMENTATION AND CHALLENGES IN PHARMACEUTICALS DEVELOPMENT

Pharmaceutical industry is constantly looking for ways to ensure and enhance product safety, quality and efficacy. However, drug recalls, manufacturing failure cost, scale up issues and regulatory burden in recent past suggest otherwise. In traditional quality by testing (QbT) approach, the product quality and performance are predominantly ensured by end product testing, with limited understanding of the process and critical process parameters. Regulatory bodies are therefore focusing on implementing quality by design (QbD), a science based approach that improves process understanding by reducing process variation and the enabling process-control strategies. In this regards, pharmaceutical industry is currently undergoing a significant transformation to streamline their R&D process, provide greater manufacturing flexibility and control, and to reduce regulatory burden. However, there is limited understanding and major concerns regarding the implementation of QbD principles in the pharmaceutical arena. The objective of this review article is therefore to provide a comprehensive understanding on various aspects of QbD, along with addressing the concerns related to its implementation.

[1]  Pedro Hernandez-Abad,et al.  Quality by design case study: an integrated multivariate approach to drug product and process development. , 2009, International journal of pharmaceutics.

[2]  H. Wu,et al.  Quality-by-Design (QbD): An integrated process analytical technology (PAT) approach for a dynamic pharmaceutical co-precipitation process characterization and process design space development. , 2011, International journal of pharmaceutics.

[3]  Andre Raw,et al.  Quality by Design: Concepts for ANDAs , 2008, The AAPS Journal.

[4]  Ed White Risk Management for Aseptic Processing , 2009 .

[5]  Shayne C. Gad,et al.  Handbook of pharmaceutical biotechnology , 2007 .

[6]  Graham McCreath,et al.  Practical Considerations for DoE Implementation in Quality By Design , 2010 .

[7]  Evdokia Korakianiti,et al.  Statistical Thinking and Knowledge Management for Quality-Driven Design and Manufacturing in Pharmaceuticals , 2011, Pharmaceutical Research.

[8]  Xiangyang Wang,et al.  Defining Process Design Space for Biotech Products: Case Study of Pichia pastoris Fermentation , 2008, Biotechnology progress.

[9]  Generic Development of Topical Dermatologic Products, Part II: Quality by Design for Topical Semisolid Products , 2013, The AAPS Journal.

[10]  Suzanne S. Farid,et al.  Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein , 2011, Biotechnology progress.

[11]  Johannes G Khinast,et al.  An integrated Quality by Design (QbD) approach towards design space definition of a blending unit operation by Discrete Element Method (DEM) simulation. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Lawrence X. Yu,et al.  Pharmaceutical Equivalence by Design for Generic Drugs: Modified-Release Products , 2011, Pharmaceutical Research.

[13]  Lawrence X. Yu Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[14]  White Paper - An Overview of Quality by Design for Generic Drugs , 2011 .

[15]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[16]  Ravikanth Kona,et al.  Quality by Design I: Application of Failure Mode Effect Analysis (FMEA) and Plackett–Burman Design of Experiments in the Identification of “Main Factors” in the Formulation and Process Design Space for Roller-Compacted Ciprofloxacin Hydrochloride Immediate-Release Tablets , 2012, AAPS PharmSciTech.

[17]  Harold S. Baseman,et al.  Risk management applications in pharmaceutical and biopharmaceutical manufacturing , 2013 .

[18]  Lilli Møller Andersen,et al.  Quality Risk Management , 2021, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[19]  Jim Joop Halman,et al.  Risks in New Product Development: Devising a Reference Tool , 2005 .